A former principal and senior research analyst at Thomas Weisel Partners, Jason Pflaum moved back to his hometown of Minneapolis in 2011 and become the president of Plum Tree Advisors, a strategic financial consulting firm. Jason Pflaum balances his professional pursuits with his dedication to finding a cure for multiple myeloma, the rare blood cancer that his wife was diagnosed with in 2011. Through awareness and fundraising efforts with the Multiple Myeloma Research Foundation (MMRF) he hopes to be a part of finding a cure not just for myeloma, but all cancers.
In a recent press release, the MMRF announced that clinicians and researchers can now access new CoMMpass Study data on the MMRF Researcher Gateway. The gateway has been updated with information from the study’s fifth interim analysis, which includes clinical material from 420 patients and complete genomic sequencing information from 190 patients participating in CoMMpass.
Through the CoMMpass Study, the MMRF fosters an open exchange of important clinical and genomic data so that researchers can better understand multiple myeloma’s molecular basis and how patients respond to therapies. The most recent interim analysis revealed new genomic changes that are linked with disease onset and progression. With the CoMMpass Study data, the MMRF believes that researchers can more rapidly generate individualized treatment methods for patients.
In a recent press release, the MMRF announced that clinicians and researchers can now access new CoMMpass Study data on the MMRF Researcher Gateway. The gateway has been updated with information from the study’s fifth interim analysis, which includes clinical material from 420 patients and complete genomic sequencing information from 190 patients participating in CoMMpass.
Through the CoMMpass Study, the MMRF fosters an open exchange of important clinical and genomic data so that researchers can better understand multiple myeloma’s molecular basis and how patients respond to therapies. The most recent interim analysis revealed new genomic changes that are linked with disease onset and progression. With the CoMMpass Study data, the MMRF believes that researchers can more rapidly generate individualized treatment methods for patients.